TNP-470 explained

TNP-470 is an methionine aminopeptidase 2 inhibitor. Although it was one of the first angiogenesis inhibitor tested in clinical trials, its potential was hampered by neurotoxic effects and lack of effectiveness.[1] [2] [3]

Notes and References

  1. Goya Grocin . Andrea . Kallemeijn . Wouter W. . Tate . Edward W. . Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity . Trends in Pharmacological Sciences . October 2021 . 42 . 10 . 870–882 . 10.1016/j.tips.2021.07.004. 34446297 . 10044/1/102175 . 237321716 . free .
  2. Kruger . E. A. . Figg . W. D. . TNP-470: an angiogenesis inhibitor in clinical development for cancer . Expert Opinion on Investigational Drugs . June 2000 . 9 . 6 . 1383–1396 . 10.1517/13543784.9.6.1383 . 11060750 . 45149960 . 1354-3784.
  3. Stadler . Walter M. . Kuzel . Timothy . Shapiro . Charles . Sosman . Jeffery . Clark . Joseph . Vogelzang . Nicholas J. . Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma . Journal of Clinical Oncology . August 1999 . 17 . 8 . 2541–2545 . 10.1200/JCO.1999.17.8.2541 . 10561320 . en . 0732-183X.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "TNP-470".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.